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2009;37:8-14.
Background:The best time to intervene in traumatic aortic injuries has
long been a matter of debate. While emergency surgery is characterized by
high morbidity and mortality, initial medical management of uncomplicated
aortic injury and subsequent delayed surgery resulted in better outcome.
Methods and results: From analysis of medical literature of the last 10
years, major paradigm shift in management of traumatic injuries includes the
use of different imaging methods for diagnosis , with a almost complete
elimination of aortography and transesophageal echocardiography in favour
of CT scan, and a significant change in method of definitive repair, shifting
from exclusively open techniques in 1997 to predominantly endovascular
repairs in 2007. At present several reports in literature provide data on
comparative results of endovascular therapy with respect open surgery,
supporting the use of stent-graft in traumatic injuries, both in acute and
chronic cases. The authors’ personal experience comprises 58 patients
treated with endovascular stent-graft repair, with no mortality or treatment
failure even during 11 years follow-up
Conclusions: For many years traumatic aortic injury has been consid-
ered a highly lethal lesion and a potential cause of death in blunt chest
trauma. Because of the lower invasivity endovascular repair can be applied in
traumatic aortic injury with very low risk and limited impact on trauma
destabilization. Long term follow-up seems indicate a substantial durability
of the procedure.
Aneurysm Rupture after EVAR: Can the Ultimate Failure be Predicted?
Schlösser F.J.V., Gusberg R.J., Dardik A., Lin P.H., VerhagenH.J.M., Moll
F.L., Muhs B.E. Eur J Vasc Endovasc Surg 2009;37:15-22.
Objectives: To provide insight into the causes and timing of AAA
rupture after EVAR.
Design: Original data regarding AAA ruptures following EVAR were
collected from MEDLINE and EMBASE databases. Data were extracted
systematically and patient and procedural characteristics were analyzed.
Results: 270 patients with AAA ruptures after EVAR were identified.
Causes of rupture included endoleaks (in 160: type IA 57, type IB 31, type
II 23, type III 26, type IV 0, endotension 9, unspecified 14), graft migration
41, graft disconnection 11 and infection 6. Most of the described AAA
ruptures occurred within 2–3 years after EVAR. Mean initial AAA diameter
was relatively large (65 mm). No abnormalities were present in 41 patients
during follow-up before rupture. Structural graft failure was described in 96
and a fatal course in 119 patients.
Conclusions: Focus of surveillance on the first 2–3 years after EVAR
may possibly reduce the AAA rupture rate, especially in patients with
increased risk of early rupture (relatively large initial AAA diameter or
presence of endoleak or graft migration). Better stent-graft durability and
longevity is required to further reduce the AAA rupture risk after EVAR.
Complete prevention will however remain challenging since AAA rupture
may occur even if no predisposing abnormalities are present.
Characterisation of Interleukin-8 andMonocyte Chemoattractant Pro-
tein-1 Expression within the Abdominal Aortic Aneurysm and their
Association with Mural Inflammation
Middleton R.K., Bown M.J., Lloyd G.M., Jones J.L., London N.J., Sayers
R.D. Eur J Vasc Endovasc Surg 2009;37:46-55.
Objectives: Abdominal aortic aneurysms (AAAs) are characterised by
chronic transmural inflammation. This study investigated the expression of
interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1)
within the AAA, and their relationship with mural inflammation.
Methods: Biopsies were obtained from 25 AAAs, 15 abdominal aortas,
and 10 atherosclerotic thoracic aortas. IL-8 and MCP-1 expression was
measured in homogenised specimens by ELISA. Infiltrate composition and
localised expression of IL-8 and MCP-1 were determined through immu-
nohistochemistry.
Results: ELISA analysis demonstrated that IL-8 and MCP-1 were
raised in the AAA compared to the controls [(IL-8, AAA vs. abdominal
aorta: 28-fold, P  .001; AAA vs. thoracic aorta: 28-fold, P  .001)
(MCP-1, AAA vs. abdominal aorta: 9-fold, P  .001; AAA vs. thoracic
aorta: 19-fold, P  .001)]. Immunohistochemistry revealed that IL-8was localised to the inflammatory infiltrate, which consisted predomi-
nantly of CD3 T- and CD20 B-lymphocytes. MCP-1 was pre-
dominantly expressed by CD68 macrophages. Increasing IL-8 expres-
sion was associated with an increase in mural inflammation, and an
increase in CD3 T-lymphocytes of CD4 phenotype within the infil-
trate population.
Conclusion: Pathways involving IL-8 and MCP-1 may be involved in
AAA pathogenesis. IL-8 may be directly involved in the chemotaxis of
TH-lymphocytes into the AAA wall.
The Development of a VBHOM-based Outcome Model for Lower
Limb Amputation Performed for Critical Ischaemia
Tang T.Y., Prytherch D.R., Walsh S.R., Athanassoglou V., Seppi V., Sadat
U., Lees T.A., Varty K., Boyle J.R. In Association with the Audit and
Research Committee of the Vascular Society of Great Britain & Ireland
(VSGBI). Eur J Vasc Endovasc Surg 2009;37:62-6.
Background: VBHOM (Vascular Biochemistry and Haematology
Outcome Models) adopts the approach of using a minimum data set to
model outcome and has been previously shown to be feasible after index
arterial operations. This study attempts to model mortality following lower
limb amputation for critical limb ischaemia using the VBHOM concept.
Methods: A binary logistic regression model of risk of mortality was
built using National Vascular Database items that contained the complete
data required by the model from 269 admissions for lower limb amputation.
The subset of NVD data items used were urea, creatinine, sodium, potas-
sium, haemoglobin, white cell count, age on and mode of admission. This
model was applied prospectively to a test set of data (n  269), which were
not part of the original training set to develop the predictor equation.
Results: Outcome following lower limb amputation could be de-
scribed accurately using the same model. The overall mean predicted risk of
mortality was 32%, predicting 86 deaths. Actual number of deaths was 86
(2  8.05, 8 d.f., p  0.429; no evidence of lack of fit). The model
demonstrated adequate discrimination (c-index  0.704).
Conclusions: VBHOM provides a single unified model that allows
good prediction of surgical mortality in this high risk group of individuals. It
uses a small, simple and objective clinical data set that may also simplify
comparative audit within vascular surgery.
Short-Term Results of A Randomized Trial Comparing Remote End-
arterectomy and Supragenicular Bypass Surgery for LongOcclusions of
the Superficial Femoral Artery [The REVAS Trial]
Gisbertz Suzanne S., Ramzan Michael, Tutein Nolthenius Rudolph P., van
der Laan Lyckle, Overtoom Tim Th. C., Moll Frans L., de Vries Jean-Paul
P.M. Eur J Vasc Endovasc Surg 2009;37:68-76.
Objective: Techniques for surgical repair of Trans-Atlantic Inter-Society
Consensus (TASC) C and D lesions of the superficial femoral artery (SFA) are
supragenicular bypass grafting or the less invasive remote endarterectomy
(RSFAE). This trial compares the patency rates of both techniques.
Design: Randomized, multicenter trial.
Materials and methods: 116 patients were randomized to RSFAE
(n  61) and supragenicular bypass surgery (n  55). Indications for
surgery were claudication (n  77), rest pain (n  21), or tissue loss
(n  18).
Results: Median hospital stay was 4 days in the RSFAE group com-
pared with 6 days in the bypass group (p  0.004). Primary patency after
1-year follow-up was 61% for RSFAE and 73% for bypass (p  0.094).
Secondary patency was 79% for both groups. Subdividing between venous
(n  25) and prosthetic grafts (n  30) shows a primary patency of 89% and
63% respectively at 1-year follow-up (p  0.086).
Conclusion: RSFAE is a minimally invasive adjunct in the treatment of
TASCC andD lesions of the SFA, with shorter admittance and a comparable
secondary patency rate to bypass. The venous bypass is superior to both
RSFAE and PTFE bypass surgery, but only 45% of patients had a sufficient
saphenous vein available.
This study is registered with ClinicalTrials.gov, number NCT00566436.
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